Clinical trials: Placebo Group
Wheezing, Asthma
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
This is a parallel, Phase 3, 2-arm study to evaluate the efficacy and long-term safety of dupilumab treatment in children 2 to <6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze.
- Trial name
- NCT06191315
- Testing
- Dupilumab
- Where
- 74 sites in United States, Argentina and 14 more
- Volunteers
- 90 people
- Sponsor
- Sanofi
Alzheimer's Disease
Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease
Clinical features in patients with the familial early onset forms and the sporadic forms of Alzheimers disease are similar, although the course of deterioration may be different.
- Trial name
- NCT00334568
- Testing
- Rosiglitazone XR (extended release) oral tablets
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ascending single- and multiple-doses of TAK-020 in healthy participants.
- Trial name
- NCT02413255
- Testing
- TAK-020
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Takeda
Heart Failure, Type 2 Diabetes Mellitus
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
The primary objective of the study was to compare the effect of sotagliflozin to placebo on total occurrences of cardiovascular (CV) death, hospitalization for heart failure [HHF], and urgent visit for heart failure [HF] in…
- Conditions
- Heart Failure, Type 2 Diabetes Mellitus, Chronic Kidney Diseases
- Trial name
- SCORED (NCT03315143)
- Testing
- Sotagliflozin
- Where
- 754 sites in United States, Argentina and 43 more
- Volunteers
- 10,584 people
- Sponsor
- Lexicon Pharmaceuticals
Schizophrenia
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)
This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning.
- Trial name
- NCT04846868
- Testing
- Iclepertin
- Where
- 116 sites in United States, Australia and 15 more
- Volunteers
- 620 people
- Sponsor
- Boehringer Ingelheim
Colorectal Cancer
Two Center Study to Determine Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.
Pancreatic, gastric, and colorectal cancers have all been shown to overexpress the gastrin gene and to be sensitive to the trophic effects of the gastrin in animal models.
- Trial name
- CC4 (NCT02223078)
- Testing
- G17DT
- Where
- United Kingdom
- Sponsor
- Cancer Advances Inc.
Primary Biliary Cholangitis
Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes
Long-Term Study to Evaluate the Safety and Efficacy in Participants with Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes (EPICS-V)
- Trial name
- EPICS-V (NCT07216235)
- Testing
- Saroglitazar magnesium 1 mg
- Where
- 3 sites in United States
- Volunteers
- 386 people
- Sponsor
- Zydus Therapeutics Inc.
Leukemia, Myeloid, Acute
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
To investigate the efficacy, safety, and pharmacokinetics of intravenous volasertib + subcutaneous low dose cytarabine in patients >= 65 years of age with previously untreated acute myeloid leukaemia, ineligible for intensive…
- Trial name
- NCT01721876
- Testing
- Volasertib, Cytarabine
- Where
- 122 sites in United States, Argentina and 23 more
- Volunteers
- 666 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Portal
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Study GT 026 is a Phase 2, multicenter, parallel group, North American, randomized, placebo controlled, double blind study. This study will enroll subjects with portal hypertension (HVPG greater than or equal to 6 mm Hg) who also…
- Trial name
- NASH-CX (NCT02462967)
- Testing
- GR-MD-02
- Where
- 46 sites in United States
- Volunteers
- 162 people
- Sponsor
- Galectin Therapeutics Inc.
Alopecia Areata
A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)
A Phase 2 double-blind, multi-site, placebo-controlled, parallel-group design to assess the efficacy, safety and dose-response characterisation of STS-01 for the treatment of mild- moderate alopecia areata.
- Trial name
- SOT01 (NCT06402630)
- Testing
- STS01
- Where
- 9 sites in United Kingdom
- Volunteers
- 158 people
- Sponsor
- Soterios Ltd
Acute Respiratory Viral Infection
Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old
The multicenter double-blind placebo-controlled randomized in parallel-group. The objective of this study is to evaluate efficacy and safety of Raphamin in the treatment of acute respiratory viral infection (ARVI) in children…
- Trial name
- NCT04918771
- Testing
- Raphamin
- Where
- 29 sites in Russia
- Volunteers
- 435 people
- Sponsor
- Materia Medica Holding
Cognitive Deficits in Schizophrenia
Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia
This is an efficacy and safety study evaluating an experimental treatment for cognitive deficits in adults with schizophrenia.
- Trial name
- NCT01077700
- Testing
- ABT-288 Low Dose, ABT-288 High Dose
- Where
- 24 sites in United States
- Volunteers
- 214 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Schizophrenia, Schizophrenia-related Psychotic Disorder
A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder
A study to compare the change in symptom severity in participants with schizophrenia or related psychotic disorder when treated with GWP42003 or placebo in conjunction with existing anti-psychotic therapy over a period of six…
- Trial name
- NCT02006628
- Testing
- GWP42003
- Where
- 14 sites in Poland, Romania and 1 more
- Volunteers
- 88 people
- Sponsor
- Jazz Pharmaceuticals
Pandemic Influenza Immunization, Healthy Volunteers
Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older
The purpose of this phase 1/2 study is to investigate the safety and immunogenicity of different doses (high, medium and low) of a second generation structurally designed (SD2) H5 messenger ribonucleic acid (mRNA) vaccine against…
- Trial name
- NCT06907511
- Testing
- Pandemic flu H5 HA mRNA SD2 vaccine
- Where
- 13 sites in United States
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Sanofi
Overweight and Obese Volunteers.
Efficacy and Safety of a Fungal Chitosan on the Body Weight Reduction in Overweight and Obesity Volunteers
The prevalence of overweight and obesity is getting more and more important in developed as well as in emerging countries. It can be defined according to the degree of fat storage by measurement of fat mass.
- Trial name
- NCT02246699
- Testing
- KiOnutrime®-Cs
- Where
- France
- Volunteers
- 114 people
- Sponsor
- Kitozyme
NSCLC
Iressa v BSC (Best Supportive Care) in First Line NSCLC
The purpose of the study is to determine if the addition of Iressa to Best Supportive Care treatment will increase the progression free survival of chemo-naïve, poor performance status patients, with stage IIIB or IV NSCLC.
- Trial name
- INSTEP (NCT00259064)
- Testing
- Gefitinib
- Where
- 36 sites in Australia, Canada and 3 more
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Study of Rivoglitazone in Type 2 Diabetes Mellitus
This is a 26-week study in subjects with type 2 diabetes currently sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy.
- Trial name
- NCT00484198
- Testing
- Pioglitazone, Rivoglitazone
- Where
- 183 sites in United States, Argentina and 16 more
- Volunteers
- 1,912 people
- Sponsor
- Daiichi Sankyo
Type 2 Diabetes Mellitus
Effect of Efpeglenatide on Cardiovascular Outcomes
Primary Objective: To demonstrate that efpeglenatide 4 and 6 mg was noninferior to placebo on 3-point major adverse cardiac events (MACE) in Type 2 diabetes mellitus (T2DM) participants at high cardiovascular (CV) risk.
- Trial name
- AMPLITUDE-O (NCT03496298)
- Testing
- Efpeglenatide (SAR439977)
- Where
- 353 sites in United States, Argentina and 26 more
- Volunteers
- 4,076 people
- Sponsor
- Sanofi
Obesity
A Study on Efficacy and Safety of Topiramate in Maintaining Weight Loss in Obese Patients Following an Intensive, Non-Pharmacologic Weight Loss Program
The purpose of this study is to compare the efficacy and safety of topiramate 96mg and 192mg daily) with placebo in the treatment of obesity following an intensive non-pharmacologic weight loss program.
- Trial name
- NCT00236600
- Testing
- topiramate
- Volunteers
- 561 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hypertension
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo
The aim is to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg to that of candesartan 32 mg alone, HCT 25 mg alone and placebo in…
- Trial name
- NCT00434967
- Testing
- Candesartan cilexetil, Hydrochlorothiazide, Candesartan/HCT 32/25 mg
- Where
- 27 sites in Belgium, Latvia and 4 more
- Volunteers
- 2,207 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.